Twentyeight Health vs Hims & Hers
Side-by-side comparison of AI visibility scores, market position, and capabilities
Twentyeight Health provides affordable telehealth and mail-order pharmacy for contraception, STI testing, and reproductive health to underserved and low-income women.
About
Twentyeight Health is a reproductive health telehealth company founded in 2019 that focuses specifically on expanding access to contraception and reproductive healthcare for underserved women, including those on Medicaid, without insurance, or in rural areas. The platform provides online consultations with licensed providers for birth control prescriptions, STI testing kits by mail, emergency contraception, and general reproductive health questions at accessible price points with Medicaid acceptance. Twentyeight raised $25M and has enrolled hundreds of thousands of patients, with a focus on the communities most affected by reproductive healthcare access gaps. The company differentiates from other telehealth platforms by prioritizing Medicaid acceptance, multilingual care, and a health equity mission rather than serving primarily the commercially insured population. Twentyeight operates in most US states and has built relationships with state health departments and safety-net healthcare organizations. As access to reproductive healthcare has become more constrained in some US states, Twentyeight's telehealth model has become an increasingly critical access point for patients who cannot easily reach in-person reproductive health services.
Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.
About
Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.